Logo image of NTUS

NATUS MEDICAL INC (NTUS) Stock Fundamental Analysis

NASDAQ:NTUS - Nasdaq - US6390501038 - Common Stock - Currency: USD

32.96  +0.03 (+0.09%)

After market: 32.96 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NTUS. NTUS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. NTUS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NTUS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NTUS was profitable.
NTUS Yearly Net Income VS EBIT VS OCF VS FCFNTUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA 2.23%
ROE 2.94%
ROIC 5.05%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NTUS Yearly ROA, ROE, ROICNTUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 5 -5 10

1.3 Margins

Industry RankSector Rank
OM 7.06%
PM (TTM) 2.65%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTUS Yearly Profit, Operating, Gross MarginsNTUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NTUS is destroying value.
Compared to 1 year ago, NTUS has more shares outstanding
The debt/assets ratio for NTUS has been reduced compared to a year ago.
NTUS Yearly Shares OutstandingNTUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M
NTUS Yearly Total Debt VS Total AssetsNTUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

NTUS has an Altman-Z score of 6.54. This indicates that NTUS is financially healthy and has little risk of bankruptcy at the moment.
NTUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.54
ROIC/WACC0.56
WACC8.98%
NTUS Yearly LT Debt VS Equity VS FCFNTUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

2.3 Liquidity

NTUS has a Current Ratio of 2.54. This indicates that NTUS is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 1.90 indicates that NTUS should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 1.9
NTUS Yearly Current Assets VS Current LiabilitesNTUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 147.06% over the past year.
Measured over the past years, NTUS shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.94% on average per year.
The Revenue has grown by 13.56% in the past year. This is quite good.
NTUS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.39% yearly.
EPS 1Y (TTM)147.06%
EPS 3Y-5.46%
EPS 5Y-5.94%
EPS Q2Q%37.5%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-3.75%
Revenue growth 5Y4.39%
Sales Q2Q%4.26%

3.2 Future

The Earnings Per Share is expected to grow by 15.74% on average over the next years. This is quite good.
The Revenue is expected to grow by 4.27% on average over the next years.
EPS Next Y22.4%
EPS Next 2Y15.52%
EPS Next 3Y15.29%
EPS Next 5Y15.74%
Revenue Next Year5.1%
Revenue Next 2Y4.79%
Revenue Next 3Y4.1%
Revenue Next 5Y4.27%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
NTUS Yearly Revenue VS EstimatesNTUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NTUS Yearly EPS VS EstimatesNTUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 26.16, NTUS can be considered very expensive at the moment.
NTUS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.95.
NTUS is valuated rather expensively with a Price/Forward Earnings ratio of 20.58.
NTUS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.99.
Industry RankSector Rank
PE 26.16
Fwd PE 20.58
NTUS Price Earnings VS Forward Price EarningsNTUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.23
NTUS Per share dataNTUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as NTUS's earnings are expected to grow with 15.29% in the coming years.
PEG (NY)1.17
PEG (5Y)N/A
EPS Next 2Y15.52%
EPS Next 3Y15.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NATUS MEDICAL INC

NASDAQ:NTUS (7/20/2022, 8:05:33 PM)

After market: 32.96 0 (0%)

32.96

+0.03 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-05 2022-05-05/amc
Earnings (Next)08-04 2022-08-04/amc
Inst Owners91.2%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner Change0%
Market Cap1.14B
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 26.16
Fwd PE 20.58
P/S 2.38
P/FCF N/A
P/OCF N/A
P/B 2.65
P/tB N/A
EV/EBITDA 17.23
EPS(TTM)1.26
EY3.82%
EPS(NY)1.6
Fwd EY4.86%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS13.83
BVpS12.46
TBVpSN/A
PEG (NY)1.17
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.23%
ROE 2.94%
ROCE N/A
ROIC 5.05%
ROICexc N/A
ROICexgc 9.3%
OM 7.06%
PM (TTM) 2.65%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 1.9
Altman-Z 6.54
F-Score8
WACC8.98%
ROIC/WACC0.56
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.06%
EPS 3Y-5.46%
EPS 5Y-5.94%
EPS Q2Q%37.5%
EPS Next Y22.4%
EPS Next 2Y15.52%
EPS Next 3Y15.29%
EPS Next 5Y15.74%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y-3.75%
Revenue growth 5Y4.39%
Sales Q2Q%4.26%
Revenue Next Year5.1%
Revenue Next 2Y4.79%
Revenue Next 3Y4.1%
Revenue Next 5Y4.27%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A